Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nylidrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nylidrin SCHEMBL159150 | 0.78 | HIF1A (1.00) | ADRB2ADRA1ACYP1A2HIF1AADRB1 | |
| Nylidrin SCHEMBL3701975 | 0.78 | HIF1A (1.00) | ADRB2ADRA1ACYP1A2HIF1AADRB1 | |
| Nylidrin SCHEMBL15517085 | 0.78 | HIF1A (1.00) | ADRB2ADRA1ACYP1A2HIF1AADRB1 | |
| Nylidrin SCHEMBL364078 | 0.77 | ADRA1A (1.00) | ADRB2ADRA1ACYP1A2HIF1AADRB1 | |
| Nylidrin SCHEMBL15512520 | 0.76 | HIF1A (0.95) | ADRB2ADRA1ACYP1A2HIF1AADRB1 | |
| Methocarbamol SCHEMBL29360915 | 0.75 | CYP1A2 (1.00) | CYP1A2LMNACYP2D6CYP3A4TSHR | |
| Methocarbamol SCHEMBL34366 | 0.75 | CYP1A2 (1.00) | CYP1A2LMNACYP2D6CYP3A4TSHR | |
| Methocarbamol SCHEMBL34365 | 0.75 | CYP1A2 (1.00) | CYP1A2LMNACYP2D6CYP3A4TSHR | |
| Nylidrin SCHEMBL5697000 | 0.71 | ADRA1A (0.68) | ADRB2ADRA1ACYP1A2HIF1AADRB1 | |
| Methocarbamol SCHEMBL2519153 | 0.71 | LMNA (0.67) | CYP1A2LMNASLC6A2HTR2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902567-A2 | TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200254070-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020139830-A2 | TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20120231047-A1 | THERAPEUTIC AGENT DELIVERY FOR THE TREATMENT OF ASTHMA VIA IMPLANTABLE AND INSERTABLE MEDICAL DEVICES | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20080051702-A1 | Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices | HERRMANN ROBERT A | 2008-02-28 | — | — | US | disclosed |